Comparing effectiveness of 3-needle approach versus 5-needle approach of genicular nerve block on pain and quality of life in chronic osteoarthritis of knee: a double blinded randomised controlled trial Authors: Megha Bhargava, Ravi Gaur, Nitesh Manohar Gonnade, G. Sarankumar, Abhay Elhence, Nitesh Gahlot Published: 2024 ABSTRACT BackgroundKnee osteoarthritis [KOA] is a common musculoskeletal disorder that is characterized by degeneration of the articular cartilage and the subchondral bone. It leads to pain and functional limitations in the joint. Genicular Nerve Blocks [GNB] or Genicular Nerve Radiofrequency Ablation [GNRFA] are pain-reducing procedures that can be used in such patients. Newer and more accurate anatomical landmarks for genicular nerves are being identified. More named genicular nerves are also being targeted for better pain relief.ObjectivesTo compare the effectiveness of ultrasound-guided genicular nerve block using 3-point approach versus 5-point approach in patients of chronic knee Osteoarthritis on pain and quality of life.Study designA double blinded randomized controlled trial.SettingDepartment of Physical Medicine and Rehabilitation [PMR], All India Institute of Medical Sciences [AIIMS], Jodhpur.MethodsPatients satisfying the inclusion and exclusion criteria and provided consent were enrolled in the study and randomized into one of the two groups: GNB-CAT or GNB-RT. The patients underwent the procedure according to the allocated group, using a drug admixture of lidocaine and triamcinolone acetonide. The total dose of steroid used was constant in both groups. The patients were advised of a post-procedure rehabilitation protocol. Pain was assessed using an 11-point NRS, the functional status of the knee was evaluated using the TUG test duration and quality of life was assessed using the QoL component of the KOOS. The outcome measures were assessed at baseline, and 1 month and 3 months.ResultsA total of 180 patients, 90 in each group, were followed for 3 months. A reduction in pain and TUG test duration was noted at 1 and 3 months post-procedure in both groups. However, there was no significant difference between the two groups except that the patients who received GNB via the 5-nerve protocol reported a higher improvement in quality of life (58.54 ± 12.01 versus 54.02 ± 13.12, p-value = 0.011) after 3 months.LimitationsA larger volume of injectate seeps through the cortices of long bones per injection site. This leads to the blockade of other smaller, unnamed nerves and non-neural pain generators around the knee joint.ConclusionsThe results revealed no significant difference between the groups; however, there was a considerable decrease in pain and TUG test durations within the groups. Consequently, neither strategy was better than the other. The group that received GNB via a 5-point method had a superior QoL-KOOS at three months following the procedure.Trial registrationThis study was registered in the Clinical Trials Registry-India [CTRI/2023/06/054401] with registration date of 26/06/2023, after approval was obtained from the Institutional Ethics Committee, All India Institute of Medical Sciences, Jodhpur (Certificate Reference Number: AIIMS/EIC/2022/4201) with a date of 23/09/2022. Background Knee osteoarthritis [KOA] is a common musculoskeletal disorder characterized by degeneration of articular cartilage and the subchondral bone. It leads to pain, stiffness, and functional decline in the affected knee joints [1]. KOA is associated with chondrocyte loss, phenotypic transformation, and remodeling of subchondral bone. Sensory innervation of the joint contributes to the inflammatory process and pain related to the disease [2]. The overall prevalence of KOA in India is approximately 28.7%, which is higher in females than males [3, 4]. Patients with chronic KOA can be offered a multimodal treatment strategy consisting of non-pharmacological, pharmacological, minimally invasive and surgical options. Educational, behavioral and psychosocial interventions also need to be integrated into the management plans for patients suffering from KOA. Exercise, weight loss in overweight/obese patients, tai chi, cane use, tibiofemoral bracing, topical nonsteroidal anti-inflammatory drugs (NSAIDs), and intra-articular glucocorticoid injections are all strongly advised by the American College of Rheumatology [ACR] in their 2019 guidelines for KOA. However, wedge insoles, non-tramadol opioids, glucosamine, chondroitin sulfate, intra-articular hyaluronic acid, prolotherapy, platelet-rich plasma [PRP], and stem cell injections are recommended against KOA [5]. Total knee arthroplasty, even though is the gold standard treatment for advanced KOA, has a limited role in patients with multiple comorbidities for whom postoperative functional outcomes are not favourable [6]. It has also been acknowledged that about a quarter of the patients who underwent TKA suffered from post-operative pain, which often lasts beyond the period of surgical healing [7]. Genicular nerve blocks [GNB] and genicular nerve radiofrequency ablations [GNRFA] were considered and tested in clinical trials as a means to alleviate post-operative knee pain and later developed as a standalone procedure even before it. GNRFA is increasingly being tested as an analogue to intra-articular glucocorticoid injections, either in conjunction with it or alone [8–10]. An increasing number of studies on genicular nerves supplying the knee capsule have unearthed variability in the anatomical origin, course and distal points of contact of these nerves with the femur or tibia [11, 12]. Figure 1 Newer and revised targets for genicular nerves, found in cadaveric investigations and tested in clinical trials, offer superior functional outcomes and provide more effective pain relief than conventional targets [13–16]. Therefore, it is pertinent that clinical research walks along anatomical studies where newer and potentially more accurate landmarks are being ascertained with each study.Fig. 1Anatomy of genicular nerves in anterior A, posterior B, medial C and lateral D views. SLGN- superolateral genicular nerve, SMGN-superomedial genicular nerve, ILGN- inferolateral genicular nerve, IMGN- inferomedial genicular nerve, RFNrecurrent fibular nerve, IPBSN- infrapatellar branch of saphenous nerve Anatomy of genicular nerves in anterior A, posterior B, medial C and lateral D views. SLGN- superolateral genicular nerve, SMGN-superomedial genicular nerve, ILGN- inferolateral genicular nerve, IMGN- inferomedial genicular nerve, RFNrecurrent fibular nerve, IPBSN- infrapatellar branch of saphenous nerve The present study aims to compare the effectiveness of the 3-nerve protocol using conventional anatomical targets for the superomedial, superolateral and inferomedial genicular nerves versus the 5-nerve protocol, wherein the revised targets for the superomedial, superolateral, inferomedial genicular nerves, recurrent fibular nerve and infrapatellar branch of the saphenous nerve will be used, on pain and quality of life in patients with chronic osteoarthritis of the knee. The primary objective of the study is to compare the severity of pain between the two groups using 11-point Numerical Rating Scale (NRS) at baseline, and 1 month and 3 months after the procedure. The secondary objective of the study is to compare the quality of life between the two groups using Quality of Life (QoL) component of Knee Injury and Osteoarthritis Outcome Score (KOOS). Materials and methods Study design This prospective, double-blinded, randomized control trial was conducted from June 2023 to June 2024 in the Department of Physical Medicine and Rehabilitation [PMR] at a tertiary care center in Western Rajasthan, India. The study protocol was approved by the Institute Ethics Committee and was registered in the Clinical Trials Registry-India [CTRI]. The last patient received the treatment on 13/02/2024. The inclusion criteria were: age > 18 years, chronic knee pain for more than 3 months, received conservative treatment for at least 3 months, diagnosed KOA according to the ACR criteria, and Grade 2–4 according to Kellgren-Lawrence classification. Most of the patients included had medial compartment osteoarthritis. However, a few patients with Grade 4 KOA had patellofemoral involvement. Grade 4 KOA patients were included if they were not candidates of TKA or were not willing for surgery. Patients were excluded if they were willing to undergo TKA, had any previous surgical intervention performed on the affected knee, presence of a concomitant or alternate diagnosis like Rheumatoid Arthritis was present, there was evidence of peripheral neuropathy, patients had uncontrolled hypertension or Diabetes Mellitus, severe neurological or psychiatric illness at presentation or any history of a bleeding diathesis. The sample size was calculated using the study conducted by Fonkoue et al. [13] using the NRS at 3 months for both the groups as a parameter. Using G* Power 3.1 software, we calculated the sample size to be 89, which was rounded to 90 in each group [total sample size = 180] to achieve a power of 80%, a two-sided level of significance of 5% and a confidence interval of 95%. Written informed consent was obtained from the patients/trusted relatives in the presence of a witness prior to enrolment in the trial. The patients were randomized into one of the two treatment groups: GNB-CAT [3-nerve protocol] and GNB-RT [5-nerve protocol]. A random draw of a block of sealed envelopes without replacement ensured a 1:1 scheme upon completion, by an independent physician who was not involved in the injection or evaluation process. All patients underwent a pre-procedure evaluation during which an exhaustive clinical and demographic history was taken. The study adheres to the CONSORT guidelines. Procedure No oral medications or sedatives were given to the study participants. Each patient was made to lie supine on the procedure table with a pillow under the popliteal fossa of the knee to be injected to ensure comfort and 30 degrees of knee flexion. The patients were examined pre-procedure for any localized skin changes, swelling or effusion. The knee to be injected was cleaned, prepared and draped under sterile aseptic precautions. The 12 MHz linear probe was cleaned and covered with a sterile plastic cover. Technique for genicular nerve block [5-nerve protocol] [15, 17, 18] Superomedial genicular nerve [SMGN] The probe was placed longitudinally on the medial aspect of the knee joint. The medial joint line was identified and the transducer was traced proximally [superiorly] to visualize the medial femoral condyle. The adductor tubercle was identified. The transducer was then placed axially and traced approximately 1 cm anterior to the adductor tubercle. This anatomical landmark does not necessitate visualization of the genicular vessels. The needle path was ascertained so that the drug is deposited 1 cm anterior to the adductor tubercle. The needle was inserted in-plane and the drug admixture was deposited at the said site after negative aspiration under USG guidance (Fig. 2).Fig. 2A, B USG probe placements for identification of superomedial genicular nerve [SMGN] target point. C USG image showing the target point for SMGN which is 1 cm anterior to the adductor tubercle of femur A, B USG probe placements for identification of superomedial genicular nerve [SMGN] target point. C USG image showing the target point for SMGN which is 1 cm anterior to the adductor tubercle of femur Superolateral genicular nerve [SLGN] The probe was placed longitudinally on the lateral aspect of the knee joint. The lateral joint line was identified and the transducer was traced proximally [superiorly] to visualize the lateral condyle-shaft junction of the femur. The transducer was rotated axially and traced posteriorly to visualize the junction of the lateral cortex and the posterior cortex of the femur. The target point for drug deposition was at the posterior edge of the lateral cortex of the femur and the superior edge of the lateral femoral condyle. The needle path was ascertained. The needle was inserted in-plane and the drug admixture was injected at the said site after negative aspiration under USG guidance (Fig. 3).Fig. 3A, B USG probe placements for identification of superolateral genicular nerve [SLGN] target point. C USG image showing the target point for SLGN which is at the junction of lateral and posterior femoral cortices, corresponding to the posterior edge of the lateral femoral cortex and superior edge of the lateral femoral condyle A, B USG probe placements for identification of superolateral genicular nerve [SLGN] target point. C USG image showing the target point for SLGN which is at the junction of lateral and posterior femoral cortices, corresponding to the posterior edge of the lateral femoral cortex and superior edge of the lateral femoral condyle Inferomedial genicular nerve [IMGN] The probe was placed longitudinally on the medial aspect of the knee joint. The medial joint line was identified and the transducer was traced distally [inferiorly] to visualize the medial condyle-shaft junction of the tibia and the distal insertion point of the medial collateral ligament [MCL]. The mid-point between the medial tibial condyle and the MCL served as the target point for IMGN. The inferomedial genicular vessels can often be seen traversing along this landmark. The needle path was ascertained. The needle was inserted in-plane and the drug admixture was injected at the said site after negative aspiration under USG guidance (Fig. 4).Fig. 4A, B USG probe placements for identification of inferomedial genicular nerve [IMGN] target point. C USG image showing the target point for IMGN which is at the mid-point of insertion of medial collateral ligament [MCL] and the medial tibial condyle A, B USG probe placements for identification of inferomedial genicular nerve [IMGN] target point. C USG image showing the target point for IMGN which is at the mid-point of insertion of medial collateral ligament [MCL] and the medial tibial condyle Recurrent fibular nerve [RFN] The probe was placed longitudinally on the lateral aspect of the knee joint. The lateral joint line was identified and the transducer was traced proximally [superiorly] to visualize the lateral condyle-shaft junction of the femur. The transducer was traced distally and Gerdy’s tubercle was identified. The transducer was then rotated axially and further traced distally [inferiorly] about 1 cm from Gerdy’s tubercle. The target point was visualized. The needle path was ascertained. The needle was inserted in-plane and the drug admixture was injected at the said site after negative aspiration under USG guidance (Fig. 5).Fig. 5A, B USG probe placements for identification of recurrent fibular nerve [RFN] target point. C USG image showing the target point for RFN which is 1 cm inferior to the Gerdy’s tubercle A, B USG probe placements for identification of recurrent fibular nerve [RFN] target point. C USG image showing the target point for RFN which is 1 cm inferior to the Gerdy’s tubercle Infrapatellar branch of saphenous nerve [IPBSN] The patellar apex and tibial tuberosity were identified by palpation and the line joining them was marked on the skin. The probe was placed longitudinally 4 cm medially to this line. The IPBSN can be identified as a thin hypoechoic line in the subcutaneous tissue. The needle is inserted in-place in the subcutaneous tissue and the drug admixture is injected over the nerve after negative aspiration under USG guidance (Fig. 6).Fig. 6A, B USG probe placements for identification of infrapatellar branch of saphenous nerve [IPBSN] target point. C USG image showing the IPBSN as a hypoechoic nerve [marked by yellow solid arrows] in the subcutaneous plane 4 cm medial to the line joining the apex of patella and tibial tuberosity A, B USG probe placements for identification of infrapatellar branch of saphenous nerve [IPBSN] target point. C USG image showing the IPBSN as a hypoechoic nerve [marked by yellow solid arrows] in the subcutaneous plane 4 cm medial to the line joining the apex of patella and tibial tuberosity Technique for genicular nerve block [3-nerve protocol] [13, 19] Superomedial genicular nerve [SMGN] The probe was placed longitudinally on the medial aspect of the knee joint. The medial joint line was identified and the transducer was traced proximally [superiorly] to visualize the medial condyle-shaft junction of the femur. The genicular artery was identified and confirmed on color Doppler. The SMGN is found in the vicinity of the artery as they travel together along the periosteum of the femur. The needle was inserted in-plane and drug admixture was deposited after bony contact, under USG visualization after a negative aspiration (Fig. 7). Fig. 7A, B USG probe placements for identification of superomedial genicular nerve [SMGN] target point. C USG image showing the target point for SMGN which is along the medial femoral cortex at the condyle-shaft junction in the vicinity of superomedial genicular vessels A, B USG probe placements for identification of superomedial genicular nerve [SMGN] target point. C USG image showing the target point for SMGN which is along the medial femoral cortex at the condyle-shaft junction in the vicinity of superomedial genicular vessels Superolateral genicular nerve [SLGN] The probe was placed longitudinally along the lateral aspect of the knee joint. The lateral joint line was identified and the transducer was traced proximally [superiorly] to visualize the lateral condylar-shaft junction of the femur. The location of the genicular artery was identified and confirmed on colour Doppler. As the SLGN travels in the vicinity of the genicular vessels along the periosteum of the femur, the needle path was decided. The needle was inserted in-plane and drug admixture was injected after bony contact under USG guidance after negative aspiration (Fig. 8).Fig. 8A, B USG probe placements for identification of superolateral genicular nerve [SLGN] target point. C USG image showing the target point for SLGN which is along the lateral femoral cortex at the condyle-shaft junction in the vicinity of superolateral genicular vessels A, B USG probe placements for identification of superolateral genicular nerve [SLGN] target point. C USG image showing the target point for SLGN which is along the lateral femoral cortex at the condyle-shaft junction in the vicinity of superolateral genicular vessels Inferomedial genicular nerve [IMGN] The probe was placed longitudinally on the medial aspect of the knee joint. The medial joint line was identified and the transducer was traced distally [inferiorly] to visualize the medial condyle-shaft junction of the tibia. The genicular artery was identified and confirmed on colour Doppler. The IMGN is found in the vicinity of the artery as they travel together along the periosteum of the tibia. The needle was inserted in-plane and drug admixture was deposited after bony contact, under USG visualization after a negative aspiration (Fig. 9).Fig. 9A, B USG probe placements for identification of inferomedial genicular nerve [IMGN] target point. C USG image showing the target point for IMGN which is along the medial tibial cortex at the condyle-shaft junction in the vicinity of inferomedial genicular vessels A, B USG probe placements for identification of inferomedial genicular nerve [IMGN] target point. C USG image showing the target point for IMGN which is along the medial tibial cortex at the condyle-shaft junction in the vicinity of inferomedial genicular vessels A needle was injected superficially without any injectate at the sites for the recurrent genicular nerve and infrapatellar branch of saphenous nerves [RFN and IPBSN] in patients of GNB-CAT to ensure uniformity among participants in both groups. The 5 sites were bandaged similarly to those in the other group and the patient was advised to follow the post-procedure regimen of medication and rehabilitation (Fig. 10).Fig. 10CONSORT diagram for the study CONSORT diagram for the study The following drug combination was used for GNB-CAT: 2 mL of a fluid mixture of lidocaine 1% (1.5 mL) plus 33 mg of triamcinolone (0.8 mL of triamcinolone 40 mg/mL) to be injected at each target site. The following drug combination was used for GNB-RT: 2 mL of a fluid mixture of lidocaine 1% (1.5 mL) plus 20 mg of triamcinolone (0.5 mL of triamcinolone 40 mg/mL) to be injected at each target site. The total dose of triamcinolone acetonide used was constant [100 mg] for each group [13]. All the patients were enrolled in a comprehensive rehabilitation program after the procedure. The exercises prescribed were according to the conventional protocol for 12 weeks. Telephonic follow-up was also performed to ensure compliance. There were no side effects from the procedures for any of the participants. Evaluation and statistical analysis Patients included in the study were evaluated by an independent blinded evaluator. The study outcomes were measured via an 11-point NRS and QoL component of KOOS was used to evaluate quality of life. The study outcomes were measured at baseline, after one and three months of the procedure. After attrition, as per intention to treat analysis, a total of 180 patients [90 in each group] were analyzed. The data collected from the patients recruited in the study was filled and computed in Google Sheets. Jamovi software version 2.3.28 was used for statistical analysis.The test used to check the association of gender, BMI category, K-L grading, associated comorbidities and presence of knee effusion between groups was the Chi-square (χ2) test.The test used to compare the ages of the two groups was the Independent samples t-test.The test used to compare baseline parameters of BMI, USG evaluation [Femoral cartilage thickness, Patellar tendon thickness, Quadriceps muscle thickness and Quadriceps tendon thickness], 11-point NRS and QoL component of KOOS was the Mann–Whitney U test. The test used to check the association of gender, BMI category, K-L grading, associated comorbidities and presence of knee effusion between groups was the Chi-square (χ2) test. The test used to check the association of gender, BMI category, K-L grading, associated comorbidities and presence of knee effusion between groups was the Chi-square (χ2) test. The test used to compare the ages of the two groups was the Independent samples t-test. The test used to compare the ages of the two groups was the Independent samples t-test. The test used to compare baseline parameters of BMI, USG evaluation [Femoral cartilage thickness, Patellar tendon thickness, Quadriceps muscle thickness and Quadriceps tendon thickness], 11-point NRS and QoL component of KOOS was the Mann–Whitney U test. The test used to compare baseline parameters of BMI, USG evaluation [Femoral cartilage thickness, Patellar tendon thickness, Quadriceps muscle thickness and Quadriceps tendon thickness], 11-point NRS and QoL component of KOOS was the Mann–Whitney U test. For interpretation, a p-value < 0.05 was considered statistically significant. Results Baseline characteristics The demographic characteristics of the study population are summarized in Table 1 and were comparable between the two groups. We conducted our study in primarily middle-aged and elderly populations, with the age of the individuals ranging from 34 to 84 years. The mean age of the sample was 58.13 ± 9.47 years and the median was 57 years. As described in various previous studies, the incidence of KOA increases with an increasing BMI. Obesity is a major reversible risk factor for the development of KOA [3, 4, 20]. The prevalence of KOA was found to be the highest in the pre-obese population of the sample and followed by patients who fell under obesity class I (Table 1). It is believed that obese patients with a higher grade of KOA (Grade 4) usually undergo surgical management and hence did not present to us for pain-relieving procedures. The median (IQR) of 11-point NRS, in the GNB-CAT cohort was 7 (2.00), whereas, in the GNB-RT cohort, it was 7 (1.00). The difference between both groups was not significant [p-value = 0.451] (Table 1). The median (IQR) of the QoL component of KOOS, in the GNB-CAT cohort was 25 (12.50), whereas, in the GNB-RT cohort, it was 31.25 (18.75). The difference between the two groups was significant [p-value = 0.015] (Table 1). Table 1Baseline characteristics of the study groupGNB-CAT Genicular Nerve Block- Classical Anatomical Targets, GNB-RT Genicular Nerve Block- Revised Targets, BMI Body mass index*Independent samples t-test# Chi-square Test (𝛘2)$ Mann- Whitney U test Table 1Baseline characteristics of the study groupGNB-CAT Genicular Nerve Block- Classical Anatomical Targets, GNB-RT Genicular Nerve Block- Revised Targets, BMI Body mass index*Independent samples t-test# Chi-square Test (𝛘2)$ Mann- Whitney U test Baseline characteristics of the study group GNB-CAT Genicular Nerve Block- Classical Anatomical Targets, GNB-RT Genicular Nerve Block- Revised Targets, BMI Body mass index *Independent samples t-test # Chi-square Test (𝛘2) $ Mann- Whitney U test The measurements of the study outcomes for both groups at different follow-ups are summarized in Table 2. The median (IQR) of 11-point NRS in GNB-CAT at baseline was 7.00 (2.00), at 1 month post-procedure, it was 2.00 (1.00) and at 3 months post-procedure, it was 3.00 (1.00). There was a significant improvement in pain scale at every follow-up (p-value < 0.001). The median (IQR) of QoL component of KOOS in GNB-CAT at baseline was 25.00 (12.50), at 1 month post-procedure, it was 62.50 (18.75) and at 3 months post-procedure, it was 56.25 (18.75). There was a significant improvement in the pain score at every follow-up (p-value < 0.001). Table 2Inter-group comparison of outcome measures at different follow-ups for Group 1: GNB-CAT and Group 2: GNB-RT Table 2Inter-group comparison of outcome measures at different follow-ups for Group 1: GNB-CAT and Group 2: GNB-RT Inter-group comparison of outcome measures at different follow-ups for Group 1: GNB-CAT and Group 2: GNB-RT The median (IQR) of 11-point NRS in GNB-RT at baseline was 7.00 (1.00), at 1 month post-procedure, it was 2.00 (1.00) and at 3 months post-procedure, it was 3.00 (1.00). There was a significant improvement in pain scale at every follow-up (p-value < 0.001). The median (IQR) of QoL component of KOOS in GNB-RT at baseline was 31.25 (18.75), at 1 month post-procedure, it was 65.63 (18.75) and at 3 months post-procedure, it was 62.50 (18.75). There was a significant improvement in pain scale at every follow-up (p-value < 0.001). There was a significant reduction in pain within both the groups but there is no significant difference in 11-point NRS at 1 month (p-value = 0.994) and 3 months (p-value = 0.087) post-procedure between both groups (Fig. 11 and Table 2). There was no significant improvement between the QoL component of KOOS at 1 month between both groups (p-value = 0.052) however, there was a substantial difference between both groups at 3 months (p-value = 0.011) (Fig. 12).Fig. 11Plot depicting the comparison of means and medians for 11-point NRS at different follow-ups in Group 1: GNB-CAT and Group 2: GNB-RT at baseline (A), at 1 month (B) and 3 months post-procedure (C)Fig. 12Plot depicting the comparison of means and medians for the QoL component of KOOS at different follow-ups in Group 1: GNB-RT and Group 2: GNB-RT at baseline (A), at 1 month (B) and 3 months post-procedure (C) Plot depicting the comparison of means and medians for 11-point NRS at different follow-ups in Group 1: GNB-CAT and Group 2: GNB-RT at baseline (A), at 1 month (B) and 3 months post-procedure (C) Plot depicting the comparison of means and medians for the QoL component of KOOS at different follow-ups in Group 1: GNB-RT and Group 2: GNB-RT at baseline (A), at 1 month (B) and 3 months post-procedure (C) There was a significant improvement in QoL component of KOOS at 3 months in the patients of Grade 2 KOA of GNB-RT cohort as compared to GNB-CAT group (p-value = 0.014). There was also a significant reduction in NRS at 3 months in the patients of Grade 3 KOA of GNB-RT group as compared to the GNB-CAT cohort (p-value = 0.023). However, there was no significant difference between the other outcome parameters between the two groups on a grade wise comparison (Table 3). Table 3Grade-wise comparison between the two groups Table 3Grade-wise comparison between the two groups Grade-wise comparison between the two groups Discussion Knee osteoarthritis (KOA) is a progressive degeneration of the joint that is multifactorial in origin. In India, KOA is a leading cause of chronic knee pain, the prevalence of which is 23–39% [21]. We conducted a study to compare the effectiveness of ultrasound-guided genicular nerve block via a 3-point approach versus a 5-point approach on pain and quality of life in patients suffering from chronic osteoarthritis of the knee joint. Our study is one of the few studies to evaluate the results of genicular nerve block using newer and seemingly more accurate anatomical landmarks for named genicular nerves. A multi-disciplinary approach to treating KOA requires the incorporation of non-pharmacological, pharmacological, and interventional methods and lifestyle changes to be incorporated into the treatment protocol. Choi et al. published the first double-blinded, randomized controlled trial performing GNRFA in patients with chronic KOA [22]. All the patients included in this study had pain reduction and functional improvement, measured at 12 weeks of procedure. This study by Choi et al. stimulated interest and paved the way for more research concerning genicular nerve blocks [GNB] and genicular nerve radiofrequency ablation [GNRFA]. Cadaveric and anatomical studies also gained pace to aid in the precise location of the targeted nerves. Analgesic block with corticosteroids and radiofrequency ablation of genicular nerves were compared in a randomized controlled trial conducted by Sinclair et al. to manage pain in patients who had undergone total knee replacement [23]. The study noted that while patients in both groups responded positively and had a significant reduction in pain relief and improvement in knee joint function, there was no significant difference between the two groups. Both groups reported similar outcomes over a six-month period. Minimally invasive pain-alleviating procedures like the GNB and GNRFA are safe and longer-lasting treatment options for patients who do not have an advanced course of the disease but still require control of pain symptoms [9, 10, 21, 24, 25]. The combination of corticosteroids with local anesthetics provides pain relief for a longer period than local anesthetics used alone. This is because of the blockade of afferent transmission of C-type pain fibres [19, 21]. Consuming multiple oral analgesics can be cumbersome for the patient and lead to non-compliance. Thus, a procedure like the GNB leads to lower oral analgesic consumption [25]. The positive results of these trials sparked interest in looking for more accurate landmarks for genicular nerves. Fonkoue et al. conducted a cadaveric study on 21 fresh knees, where they identified newer anatomical landmarks for fluoroscopic-guided genicular nerve blockade [26]. The revised landmarks proved to be accurate to 100% for 4 out of 5 consistent genicular nerves- SMGN, IMGN, IPBSN and RGN. The new landmark for SLGN was found to be accurate 90% of the time. Fonkoue et al. conducted another cadaveric study to validate an ultrasound-guided protocol for new landmarks. [18] 14 fresh cadaveric knees were selected and the 5 consistent genicular nerves- SMGN, IMGN, SLGN, IPBSN and RGN were identified. This study showed accuracy in USG-guided GNRFA of all five nerves with the revised anatomical targets. The authors suggested that the revised anatomical targets could lead to better therapeutic effects. However, the authors did not create visibly identifiable radio-frequency lesions in the cadaveric knees and instead used a black mark as a surrogate for localization. Also, a clinical correlation of the revised anatomical targets to truly analyze their accuracy and long-term effects would have been preferential. A randomized controlled trial conducted by Fonkoue et al. compared the efficacy of classical and revised anatomical targets for pain and function in chronic KOA patients treated with corticosteroids and lignocaine [13]. The revised technique was found to be more efficacious at alleviating pain and improving functional outcomes in the patients on follow-up. However, this study had certain limitations. The volume injected per site was greater and did not allow clear delineation of sensory areas supplied by the targeted nerves. A randomized controlled trial conducted by Kose et al. compared the 3-nerve protocol versus the 5-nerve protocol via USG-guided GNRFA in 80 patients [27] SMGN, IMGN, and SLGN remained common in both groups, whereas IPBSN and RFN were additionally lesioned in the 5 nerve protocol. The patients were followed up at 1 week, 1 month, 3 months and 6 months after the procedure and the outcome measures [NRS and WOMAC] were assessed. This was probably the first RCT conducted comparing these two protocols. The 5-nerve technique provided better pain relief at all follow-up intervals than the 3-nerve technique. Skyrocketing pain-alleviating procedures like GNB and GNRFA have also boomed research in this sector. Suboptimal localization of the targeted nerves eventually leads to suboptimal outcomes. Therefore, it is pertinent that clinical research walks along anatomical studies where newer and potentially more accurate landmarks are being ascertained with each study. Our study is perhaps the first prospective comparative study to be conducted for ultrasonography-guided genicular nerve blocks, wherein the newer and classical landmarks have been compared. In our study, there is a significant reduction in pain as measured by 11-point NRS and improvement in the QoL component of KOOS within both groups. However, the 11-point NRS at 1 month and 3 months post-procedure between both groups was comparable (Table 2). There is no significant improvement in the QoL component of KOOS at 1 month between both groups; however, there is a substantial difference between both groups at 3 months, showing a better QoL score in GNB-RT group. None of our patients complained of difficulty in walking, altered sensations, bruising or prolonged pain at injection site during the post-procedure period. The response of patients with different K-L grades of KOA to genicular nerve blocks can vary. It is imperative that more analysis be done to understand this variation better. It is postulated that patients with lower grades of KOA (Grade 2) respond better to genicular nerve blocks because of relatively preserved joint structure. However, patients with hgiher grades of KOA (Grade 3–4) have significant structural damage to their knee joint with a multifactorial origin of pain. Central sensitization may also occur in patients with Grade 3–4 KOA who have a chronic history of pain [28]. In our study, we found that the there was no significant difference between the two groups in the grade-wise comparison except for two instances where the 5 point GNB approach performed better. There was a significant improvement in QoL score at 3 months in the Grade 2 KOA of GNB-RT and NRS at 3 months in Grade 3 GNB-RT cohorts. There are certain limitations to our study. First, the baseline scores on the two outcome measures: 11-point NRS and QoL component of KOOS were significantly different in both groups. Second, the volume of injectate used was 2 mL and 2.5 mL at each side for GNB-CAT and GNB-RT, respectively, keeping a constant total dose of corticosteroid (100 mg) in the mixture. Large volumes of injectate such as ours are justifiable for performing genicular nerve blocks, as per the literature [13, 29]. However, large volumes of injectate tend to seep through the cortex, covering an increased area and spreading beyond the area of the lesion created in GNRFA. A higher volume of injectate in diagnostic GNBs can even lead to false-positive tests for predicting a successful outcome of GNRFA. A monopolar RFA needle creates a lesion of 0.5 to 1 cm3 [30]. A study done by McCormick et al. says that using a local anesthetic volume of 1 mL at each nerve site in a diagnostic GNB did not improve the rate of treatment success for conventional GNRFA [31]. A volume beyond 0.5 mL might block other named and/or smaller unnamed branches of these genicular nerves and even non-neural pain generators in the knee joint, leading to a better result than anticipated or even plausible. The accurate localization of anatomical targets for the five targeted nerves (SMGN, SLGN, IMGN, RFN, and IPBSN) is likely compromised by the high amount employed per injection site in our investigation. We can infer that since the lesion created by GNRFA is smaller, more precise localization of the targeted nerves can be better utilized in RFA procedures over GNBs, even though measurements of long-term outcomes are found to be similar in both GNRFA and GNBs [21]. While performing genicular nerve blocks with a volume of 1 mL or more, both the classical and revised anatomical landmarks provide a similar effect on pain reduction, quality of life and knee function for as long as 3 months. We also acknowledge the lack of a longer follow-up period to precisely determine the duration of action of interventional pain relieving procedures like GNBs. Conclusion Genicular nerve blocks using an admixture of corticosteroids and local anesthetics are safe, effective, minimally invasive and cost-effective treatment options for patients suffering from chronic knee osteoarthritis. Three months after the procedure, the results showed no significant difference between both groups; however, there was a considerable decrease in pain within the groups. Consequently, neither strategy was better than the other. A 3-nerve approach to genicular nerve block (GNB) works just as brilliantly and it is unnecessary to prick a patient to target more nerves. The group that received GNB via a 5-nerve protocol had a higher QoL component of KOOS at three months following the procedure, suggesting that the 5-nerve protocol resulted in a better quality of life in the long-term. A follow-up study may be required to accurately assess the duration of pain relief provided by the GNB. Our study highlights the importance of measuring quality of life scores and knee function in addition to pain scores because knee osteoarthritis is as much a biomechanical problem as it is a physical problem. Approximately seventy years after the first epidural steroid injection and fifty years after the first lumbar facet joint RFA, these procedures are still evolving. This is why additional research on peripheral nerve blocks, like GNB, is necessary. These blocks inhibit the sensory pain signals coming from the osteoarthritic joint and support a believable return of function and lower limb mobility. These procedures can also play an incremental role in reducing the healthcare-related cost of a degenerative disease such as osteoarthritis for patients. With better software and sensor-based systems available in research centers across the world, it is the need of the hour to utilize them and analyze the gait kinematics and knee function of such pain-relieving procedures on patients with KOA. Credible literature on gait parameters following such procedures will lead to a better understanding of the altered and improved lower limb biomechanics in osteoarthritis. The psychological effects of pain and activity limitation have more psychosocial implications than are covered in the literature and need to be pondered.